Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma
Authors
Keywords
-
Journal
Hepatology International
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-21
DOI
10.1007/s12072-023-10603-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma
- (2023) Zhewen Xiong et al. GUT
- Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision making
- (2023) Renumathy Dhanasekaran et al. HEPATOLOGY
- Combination immunotherapy for hepatocellular carcinoma
- (2023) Lorenza Rimassa et al. JOURNAL OF HEPATOLOGY
- Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
- (2023) Ruiwen Ruan et al. Molecular Cancer
- Lenvatinib as second-line treatment after atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma –clinical results show importance of hepatic reserve function
- (2023) Atsushi Hiraoka et al. ONCOLOGY
- Priming a vascular-selective cytokine response permits CD8+ T-cell entry into tumors
- (2023) Dae Joong Kim et al. Nature Communications
- Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective
- (2023) Hironori Koga et al. Clinical and Molecular Hepatology
- Lenvatinib recruits cytotoxic GZMK+CD8 T cells in hepatocellular carcinoma
- (2023) Tomoharu Yamada et al. Hepatology Communications
- Direct and indirect regulation of the tumor immune microenvironment by VEGF
- (2022) Yuqing Zhang et al. JOURNAL OF LEUKOCYTE BIOLOGY
- The impact of VEGF on cancer metastasis and systemic disease
- (2022) Yunlong Yang et al. SEMINARS IN CANCER BIOLOGY
- The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma
- (2022) Romain Donne et al. HEPATOLOGY
- Metabolic communication in the tumour–immune microenvironment
- (2022) Kung-Chi Kao et al. NATURE CELL BIOLOGY
- Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing
- (2022) Xiaopei Hao et al. Redox Biology
- Regulation of PD-L1 expression in the tumor microenvironment
- (2021) Ming Yi et al. Journal of Hematology & Oncology
- NASH limits anti-tumour surveillance in immunotherapy-treated HCC
- (2021) Dominik Pfister et al. NATURE
- Advances in immunotherapy for hepatocellular carcinoma
- (2021) Bruno Sangro et al. Nature Reviews Gastroenterology & Hepatology
- Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCC
- (2021) Chenhe Yi et al. HEPATOLOGY
- Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies
- (2021) Shohei Koyama et al. Journal for ImmunoTherapy of Cancer
- Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
- (2021) Hideki Iwamoto et al. Cancers
- Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies
- (2021) Yusuke Adachi et al. CANCER RESEARCH
- The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma
- (2021) Jie Zhu et al. Cancer Medicine
- First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials
- (2021) Giuseppe Cabibbo et al. Liver Cancer
- Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib
- (2021) Fabio Scirocchi et al. Frontiers in Oncology
- Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events
- (2020) Hideki Iwamoto et al. Cancers
- FGF2 alters macrophage polarization, tumour immunity and growth and can be targeted during radiotherapy
- (2020) Jae Hong Im et al. Nature Communications
- Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
- (2019) Yu Kato et al. PLoS One
- The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity
- (2019) Sangeetha Palakurthi et al. Cancer Immunology Research
- The Role of Lipid Metabolism in T Lymphocyte Differentiation and Survival
- (2018) Duncan Howie et al. Frontiers in Immunology
- Reductions in Myeloid-Derived Suppressor Cells and Lung Metastases using AZD4547 Treatment of a Metastatic Murine Breast Tumor Model
- (2014) Li Liu et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Survival and Migration of Human Dendritic Cells Are Regulated by an IFN- -Inducible Axl/Gas6 Pathway
- (2009) S. Scutera et al. JOURNAL OF IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now